Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.75 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.72 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508951 | 0.93 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL30363045 | 0.92 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14946399 | 0.92 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574074 | 0.92 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929515 | 0.92 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574075 | 0.92 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14946391 | 0.92 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929355 | 0.92 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL15930974 | 0.88 | IMPDH2 (0.79) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL113725 | 0.87 | IMPDH2 (0.60) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| WO-2021064421-A1 | TREATMENT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-08 | — | — | WO | disclosed |
| US-8841422-B2 | Human androgen receptor alternative splice variants | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120156770-A1 | HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-06-21 | — | — | US | disclosed |
| US-8133724-B2 | Human androgen receptor alternative splice variants as biomarkers and therapeutic targets | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100068802-A1 | NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-03-18 | — | — | US | disclosed |
| US-7368551-B2 | Comprises nucleotide sequence coding methyltransferase for use as tool in diagosing tumor disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040234997-A1 | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof | THE GENERAL HOSPITAL CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | IMPDH2 2469/4885IMPDH1 2279/4885TAS1R3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.